Acquisition of Pelican Therapeutics (Tables)

6 Months Ended

Jun. 30, 2018

Business Combinations [Abstract]

Schedule of Assets Acquired and Liabilities Assumed in Acquisition

The purchase price has been allocated to the assets and liabilities as follows: 

Aggregate consideration:
Cash consideration	$	500,000
Stock consideration	$	1,052,000
Contingent consideration	$	2,385,000
Total Consideration	$	3,937,000
Purchase price allocation:
Cash acquired	$	31,199
In-process R&D	$	5,866,000
Goodwill	$	2,189,338
Deferred tax liability	$	(2,111,760	)
Net liabilities assumed	$	(1,102,777	)
Fair value of non-controlling interest	$	(935,000	)
Total purchase price	$	3,937,000

Schedule of Pro Forma Financial Information for Acquisition

	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Revenue	$	1,143,177		$	411,250		$	1,895,704		$	435,490
Net loss		(4,246,805	)		(3,310,791	)		(7,980,032	)		(6,940,735	)
Net loss: Non-controlling interest		(196,734	)		(90,508	)		(403,195	)		(219,142	)
Net loss attributable to Heat Biologics, Inc.	$	(4,050,071	)	$	(3,220,283	)	$	(7,576,837	)	$	(6,721,593	)
Net loss per share attributable to Heat Biologics, Inc.—basic and diluted	$	(0.27	)	$	(0.88	)	$	(0.77	)	$	(2.07	)